Anavex Life Sciences (NASDAQ: NASDAQ:) is positioned as a potential short-squeeze stock, as its share prices are climbing due to positive developments, increasing institutional and analyst backing, while short-sellers are reacting by selling during the price increase. At the end of November, short interest reached over 23%, likely remaining high since it marked a one-year peak, indicating strong conviction and ample potential for a short squeeze.
The upward movement that started in late October was fueled by promising results from a 2b/3 study, which demonstrated a remarkable 36% reduction in Alzheimer’s progression among the target demographic. With a projected market value exceeding $15 billion, this news is beneficial for both the pharmaceutical firm and its investors. Additionally, various indicators suggest that a short squeeze may be on the horizon. The once-daily treatment is user-friendly and offers a safer alternative to competitors that require oral administration, likely simplifying monitoring processes and potentially disrupting the market.
This treatment, known as Anavex 2-73 or blarcamesine, exhibited even greater efficacy—close to 50%—among a smaller subgroup. It could also be viable for a wide array of CNS disorders, with sales potentially surpassing $20 billion annually. The company is poised to initiate sales soon, having already applied for marketing approval in the EU, which it could receive as early as the first half of 2025, potentially leading to substantial revenue generation by year-end.
Positive Analyst and Institutional Support for Anavex Stock
Analysts hold an optimistic view on the stock but have yet to revise their revenue and earnings forecasts to reflect the potential of blarcamesine and its market-disruptive implications. Coverage is somewhat limited, with only four analysts tracked by MarketBeat, suggesting a likely cycle of significant upgrades and increased coverage ahead. Current forecasts remain strong, predicting over $8 billion in annual sales and $40 in earnings per share by 2032. However, there are no projected revenues or earnings for 2025, and the $8 billion target seems conservative considering blarcamesine’s full potential, implying that significant earnings upgrades could commence early in 2025.
Analysts’ sentiment and price targets are increasingly bullish. The consensus among the four is a Buy rating with a price target of $43, which represents a potential upside of about 400% above a crucial resistance point. The latest price targets, set following the announcement of blarcamesine results, reflect this outlook and are likely to be followed by expanded coverage and higher targets in 2025. A critical point to note is that these consensus targets notably exceed the $10.50 resistance, which, if breached, could be achieved rapidly.
Institutional activity is also on the rise, likely continuing or strengthening through 2025. At present, institutions own approximately 32% of the stock and have shown a pattern of consistent buying each quarter in 2024. In Q4, buying surpassed selling by nearly 1.5:1, reaching a near two-year peak as firms like Charles Schwab (NYSE:) and Vanguard Group enhance their positions.
Technical Indicators Suggest Strong Upside for Anavex Life Sciences
The technical outlook for Anavex shares appears robust. The market is demonstrating strong upward support at critical moving averages, supported by the MACD and stochastic indicators. This suggests that upward price momentum is building, with sufficient room remaining for growth before becoming overbought. A breakout past the critical resistance point seems probable.
A key target for optimistic traders is a move above the essential $10.50 level, reflecting a reversal pattern previously established at $7.15. This would place the market around $17.65, which is still below the analyst consensus. In the bullish scenario, surpassing the critical resistance could yield a 230% gain from the bottom of the head-and-shoulders reversal pattern to its neckline, projecting a price of $35—a significant upward move yet still short of the analysts’ consensus.
Original Post
